The content on this site is intended for healthcare professionals only
Dr Chopra talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about a newly discovered mechanism of action for immunomodulatory thalidomide analogues.
These act by modulating the way certain proteins are degraded, thus preventing the growth of certain tumours such as lymphoma.
This also negatively affects B-Cell development, but in turn activates T-Cells.
The therapy could be combined with other antibodies and vaccines.
SIOG 2024: Updates in haematology
Understanding the remaining unmet needs in a post ASCT NDMM setting
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
